Published in:
12-12-2023 | Ozanimod | Concise Commentary
Concise Commentary: Ozanimod in Real Life—Plus ça Change, Plus C’est la Même Chose
Authors:
Gionata Fiorino, Mariangela Allocca, Silvio Danese
Published in:
Digestive Diseases and Sciences
|
Issue 2/2024
Login to get access
Excerpt
Ozanimod is the first-in-class sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis (UC), representing a valid alternative to monoclonal antibodies (mAb) and Janus kinase inhibitors (JAKi) in patients with moderate-to-severe active disease [
1]. Data from the TOUCHSTONE program showed that ozanimod was significantly superior to placebo in inducing and maintaining remission at 10 and 52 weeks after treatment initiation [
2]. The safety profile was good, since infections of any severity and transaminase elevations were the only reported adverse events significantly more frequent in patients receiving ozanimod compared with placebo, notwithstanding the low absolute numbers in both study arms. …
